166 related articles for article (PubMed ID: 29066038)
1. Assessing Responsiveness of Health Systems to Drug Safety Warnings.
Gerlach LB; Kim HM; Yosef M; Sales AE; Stano C; Kales HC; Zivin K
Am J Geriatr Psychiatry; 2018 Apr; 26(4):476-483. PubMed ID: 29066038
[TBL] [Abstract][Full Text] [Related]
2. Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning.
Gerlach LB; Kales HC; Maust DT; Chiang C; Stano C; Choe HM; Zivin K
Am J Geriatr Psychiatry; 2017 Apr; 25(4):407-414. PubMed ID: 28012712
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?
Gerlach LB; Kim HM; Yosef M; Kales HC; Henry J; Zivin K
J Am Geriatr Soc; 2018 Aug; 66(8):1562-1566. PubMed ID: 29972590
[TBL] [Abstract][Full Text] [Related]
4. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Olfson M; Marcus SC; Druss BG
Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
[TBL] [Abstract][Full Text] [Related]
5. Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Bushnell GA; Stürmer T; Swanson SA; White A; Azrael D; Pate V; Miller M
Psychiatr Serv; 2016 Mar; 67(3):302-9. PubMed ID: 26567938
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of Veterans Affairs Health Care System to Zolpidem Safety Warnings.
Kim HM; Gerlach LB; Yosef M; Stano C; Conroy DA; Valenstein M; Pfeiffer PN; Sales AE; Zivin K
J Clin Sleep Med; 2018 Jul; 14(7):1135-1141. PubMed ID: 29991420
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Zivin K; Pfeiffer PN; Bohnert AS; Ganoczy D; Blow FC; Nallamothu BK; Kales HC
Am J Psychiatry; 2013 Jun; 170(6):642-50. PubMed ID: 23640689
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder.
Treviño LA; Ruble MW; Treviño K; Weinstein LM; Gresky DP
Psychiatr Serv; 2017 Feb; 68(2):199-202. PubMed ID: 27691378
[TBL] [Abstract][Full Text] [Related]
9. How much to worry about the FDA warning in the use of citalopram?
Wang SM; Pae CU
Expert Rev Neurother; 2013 Aug; 13(8):883-6. PubMed ID: 23965162
[TBL] [Abstract][Full Text] [Related]
10. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.
Lu CY; Zhang F; Lakoma MD; Madden JM; Rusinak D; Penfold RB; Simon G; Ahmedani BK; Clarke G; Hunkeler EM; Waitzfelder B; Owen-Smith A; Raebel MA; Rossom R; Coleman KJ; Copeland LA; Soumerai SB
BMJ; 2014 Jun; 348():g3596. PubMed ID: 24942789
[TBL] [Abstract][Full Text] [Related]
11. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration.
Sankar A; Swanson KM; Zhou J; Jena AB; Ross JS; Shah ND; Karaca-Mandic P
JAMA Netw Open; 2021 Dec; 4(12):e2136662. PubMed ID: 34851398
[TBL] [Abstract][Full Text] [Related]
12. The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies.
Bobo WV; Epstein RA; Hayes RM; Shelton RC; Hartert TV; Mitchel E; Horner J; Wu P
Arch Womens Ment Health; 2014 Feb; 17(1):17-26. PubMed ID: 24196827
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.
Pae CU; Wang SM; Lee SJ; Han C; Patkar AA; Masand PS
Expert Opin Drug Saf; 2014 Feb; 13(2):197-205. PubMed ID: 24131458
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram.
Friesen KJ; Bugden SC
Drug Healthc Patient Saf; 2015; 7():139-45. PubMed ID: 26316822
[TBL] [Abstract][Full Text] [Related]
15. Trends in Incident Varenicline Prescribing Among Veterans Following the US Food and Drug Administration Drug Safety Warnings.
Gerlach LB; Van T; Kim HM; Chang MM; Bohnert KM; Zivin K
J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936245
[No Abstract] [Full Text] [Related]
16. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Changes in Citalopram Prescribing Patterns Following a US Food and Drug Administration Alert: A Retrospective Cohort Study.
Fabo KR; Nye AM; Gagliardi JP; Dennis CR; Muzyk AJ
Prim Care Companion CNS Disord; 2015; 17(1):. PubMed ID: 26137354
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
Cowart K; Worley M; Rouby NE; Sando K
Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
[No Abstract] [Full Text] [Related]
19. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
20. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.
Katz LY; Kozyrskyj AL; Prior HJ; Enns MW; Cox BJ; Sareen J
CMAJ; 2008 Apr; 178(8):1005-11. PubMed ID: 18390943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
